scispace - formally typeset
D

David O. Morgan

Researcher at University of California, San Francisco

Publications -  158
Citations -  30459

David O. Morgan is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Cyclin-dependent kinase & Phosphorylation. The author has an hindex of 73, co-authored 153 publications receiving 29329 citations. Previous affiliations of David O. Morgan include Aaron Diamond AIDS Research Center & University of California, Berkeley.

Papers
More filters
Journal ArticleDOI

Principles of CDK regulation

TL;DR: The activity of cyclin-dependent kinases is controlled by four highly conserved biochemical mechanisms, forming a web of regulatory pathways unmatched in its elegance and intricacy.
Journal ArticleDOI

Cyclin-dependent kinases: engines, clocks, and microprocessors.

TL;DR: This work has shown that Cdk activity is governed by a complex network of regulatory subunits and phosphorylation events whose precise effects on Cdk conformation have been revealed by recent crystallographic studies.
Journal ArticleDOI

Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle

TL;DR: Results provide further evidence that in all eukaryotes assembly of a cyclin-Cdk complex is an important step in the biochemical pathway that controls cell proliferation during G1.
Journal ArticleDOI

A chemical switch for inhibitor-sensitive alleles of any protein kinase

TL;DR: A chemical genetic strategy for sensitizing protein kinases to cell-permeable molecules that do not inhibit wild-type kinases is described, allowing for rapid functional characterization of members of this important gene family.
Journal ArticleDOI

Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-deoxyglucose

TL;DR: It is shown that replacement of one or both of the twin tyrosines (residues 1162 and 1163) with phenylalanine results in a dramatic reduction in or loss of insulin-activated autophosphorylation and kinase activity in vitro.